Cor Vasa 2022, 64(3):316-319 | DOI: 10.33678/cor.2022.034

(Vericiguat - soluble guanylate cyclase stimulator, in therapy of heart failure)

Vojtěch Melenovský
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Chronic heart failure is associated with reduced bioavailability of nitric oxide (NO) in the myocardial tissue and in the kidney, leading to fibrosis, inflammation and pathologic hypertrophy. It is possible to stimulate directly NO-cGMP signaling pathway by stimulating soluble guanylate cyclase (sGC) that represents an endogenous receptor for NO. Direct sGC stimulator vericiguat (Verquvo®) is a drug developed specifically for patients with chronic heart failure and that has minimal hypotensive effects, has no significant drug interactions and can be used also in advanced renal dysfunction. Vericiguat was effectively tested in population of patients with worsening heart failure (VICTORIA global trial) in which it reduced risk of cardiovascular death or hospitalization for heart failure. Vericiguat represents a new therapeutic option for heart failure, especially in subjects where other therapies are limited by hypotension or development of cardiorenal syndrome.

Keywords: Cardiorenal syndrome, Heart failure, Pharmacotherapy, Nitric oxide, Soluble guanylate cyclase, Vericiguat

Received: March 22, 2022; Revised: March 22, 2022; Accepted: April 3, 2022; Published: June 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melenovský V. (Vericiguat - soluble guanylate cyclase stimulator, in therapy of heart failure). Cor Vasa. 2022;64(3):316-319. doi: 10.33678/cor.2022.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Emdin M, Aimo A, Castiglione V, et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. J Am Coll Cardiol 2020;76:1795-1807. Go to original source... Go to PubMed...
    2. Sandner P, Follmann M, Becker-Pelster E, et al. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol 2021. doi: 10.1111/bph.15698. Epub ahead of print. Go to original source... Go to PubMed...
    3. Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem 2017;60:5146-5161. Go to original source... Go to PubMed...
    4. Gheorghiade M, Greene SJ, Butler J, et al.; SOCRATES- -REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 2015;314:2251-2262. Go to original source... Go to PubMed...
    5. Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail 2020;22:1675-1683. Go to original source... Go to PubMed...
    6. Armstrong PW, Pieske B, Anstrom KJ, et al.; on behalf of the VICTORIA Study Group. Vericiguat in Patients With Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:1883-1893. Go to original source... Go to PubMed...
    7. Butler J, Anstrom KJ, Armstrong PW. Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. Circulation 2020;142:717-719. Go to original source... Go to PubMed...
    8. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    9. Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation 2021;144:1489-1499. Go to original source... Go to PubMed...
    10. Lam CSP, Mulder H, Lopatin Y, et al.; VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc 2021;10:e021094. Go to original source... Go to PubMed...
    11. Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC Heart Fail 2020;8:931-939. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes